Publicaciones en colaboración con investigadores/as de Instituto de Investigación Sanitaria de Navarra (18)

2024

  1. Mucus-penetrating and permeation enhancer albumin-based nanoparticles for oral delivery of macromolecules: Application to bevacizumab

    Drug Delivery and Translational Research, Vol. 14, Núm. 5, pp. 1189-1205

  2. Targeting and activation of macrophages in leishmaniasis. A focus on iron oxide nanoparticles

    Frontiers in Immunology, Vol. 15

2023

  1. Next generation of selenocyanate and diselenides with upgraded leishmanicidal activity

    Bioorganic Chemistry, Vol. 138

2022

  1. Effect of topical berberine in murine cutaneous leishmaniasis lesions

    Journal of Antimicrobial Chemotherapy, Vol. 77, Núm. 4, pp. 1072-1081

  2. Norbornene and Related Structures as Scaffolds in the Search for New Cancer Treatments

    Pharmaceuticals, Vol. 15, Núm. 12

2021

  1. 3,5-Dimethyl-4-isoxazoyl selenocyanate as promising agent for the treatment of Leishmania infantum-infected mice

    Acta Tropica, Vol. 215

  2. Changes in the nanoparticle uptake and distribution caused by an intramacrophagic parasitic infection

    Nanoscale, Vol. 13, Núm. 41, pp. 17486-17503

  3. Library of selenocyanate and diselenide derivatives as in vivo antichagasic compounds targeting trypanosoma cruzi mitochondrion

    Pharmaceuticals, Vol. 14, Núm. 5

  4. New phosphoramidates containing selenium as leishmanicidal agents

    Antimicrobial Agents and Chemotherapy, Vol. 65, Núm. 10

  5. Oral Efficacy of a Diselenide Compound Loaded in Nanostructured Lipid Carriers in a Murine Model of Visceral Leishmaniasis

    ACS Infectious Diseases, Vol. 7, Núm. 12, pp. 3197-3209

  6. Selenium Derivatives as Promising Therapy for Chagas Disease: In Vitro and in Vivo Studies

    ACS Infectious Diseases, Vol. 7, Núm. 6, pp. 1727-1738

2020

  1. Berberine-loaded liposomes for the treatment of leishmania infantum-infected balb/c mice

    Pharmaceutics, Vol. 12, Núm. 9, pp. 1-18

2019

  1. Evaluation of skin permeation and retention of topical dapsone in murine cutaneous leishmaniasis lesions

    Pharmaceutics, Vol. 11, Núm. 11

2018

  1. Combination of paromomycin plus human anti-TNF-α antibodies to control the local inflammatory response in BALB/ mice with cutaneous leishmaniasis lesions

    Journal of Dermatological Science, Vol. 92, Núm. 1, pp. 78-88

2017

  1. A combination of nanosystems for the delivery of cancer chemoimmunotherapeutic combinations: 1-Methyltryptophan nanocrystals and paclitaxel nanoparticles

    Pharmacological Research, Vol. 126, pp. 77-83

  2. Selenium entities: Promising scaffolds for the treatment of cancer and leishmania

    Current Organic Synthesis, Vol. 14, Núm. 8, pp. 1075-1081

  3. Skin vaccination using microneedles coated with a plasmid DNA cocktail encoding nucleosomal histones of Leishmania spp.

    International Journal of Pharmaceutics, Vol. 533, Núm. 1, pp. 236-244

2015

  1. Assessment of β-lapachone loaded in lecithin-chitosan nanoparticles for the topical treatment of cutaneous leishmaniasis in L. major infected BALB/c mice

    Nanomedicine: Nanotechnology, Biology, and Medicine, Vol. 11, Núm. 8, pp. 2003-2012